Alta Partners

Transcarent Raises $126 Million Series D

Retrieved on: 
星期四, 五月 2, 2024
Software, Telemedicine, Virtual Medicine, Managed Care, General Health, Health, Artificial Intelligence, Health Technology, Technology, Gross domestic product, Pharmacy, Investment, AI, EVP, Love, Alta Partners, Memorial Hermann Health System, Confusion, Data science, Partner (business rank), Patient, Human Capital, Bayer, Acquisition, GDP, Multimedia, Mental health, Center of excellence, Merck, Series, Ecosystem

“Everyone asked, 'can you make it easier for our people to access high-quality, affordable care?', and we have. Transcarent is the One Place for Health and Care,” said Glen Tullman, Transcarent Chief Executive Officer. “One platform --- your mobile phone --- for everything you want and need. And an experience people don’t just like but love. High-quality care and cost reductions with a relentless focus on quality. Just what the doctor ordered.”

Key Points: 
  • It is the only platform that brings together medical, surgery, pharmacy, and mental health care into one place.
  • Transcarent is the One Place for Health and Care,” said Glen Tullman, Transcarent Chief Executive Officer.
  • In 2023, Transcarent completed the successful acquisition and integration of the 98point6 AI-powered virtual care platform and care business, which includes the affiliated Transcarent Clinic.
  • Today, more than 4.3 million people have access to Transcarent through their employer or health plan.

SatixFy Announces Full Year 2023 Results

Retrieved on: 
星期五, 三月 29, 2024
Technology, Hardware, Satellite, LEO, Research, European Space Agency, Device, MDA, Application-specific integrated circuit, Cash, Travel, SATX, Insurance, Marketing, Alta Partners, Investment, Research and development, Annual report, RSU, Cryptocurrency

SatixFy Communications Ltd. (the “Company” or “SatixFy”) (NYSE AMERICAN: SATX), a pioneering force in next-generation satellite communication systems driven by in-house developed chipsets, has released its consolidated financial results for the full year period ended December 31, 2023.

Key Points: 
  • SatixFy Communications Ltd. (the “Company” or “SatixFy”) (NYSE AMERICAN: SATX), a pioneering force in next-generation satellite communication systems driven by in-house developed chipsets, has released its consolidated financial results for the full year period ended December 31, 2023.
  • The decrease in gross profit and margin due to the Company’s engagement in 2023 in projects which carry lower gross margins compared to 2022.
  • Nir Barkan, Acting Chief Executive Officer of SatixFy, commented, “2023 was marked by strategic advancements and solid progress within our product development and customer engagements.
  • “SatixFy is at a key inflection point in the industry, driven in-part by the fast-growing Low Earth Orbit ('LEO') low-latency satellite market providing broad data coverage anywhere, anytime.

Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors

Retrieved on: 
星期一, 三月 25, 2024
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Toxicity, CDK7, Apoptosis, Hebrew University of Jerusalem, CRH, CRi, AML, Patient, Immunology, Acute myeloid leukemia, Cancer, Medicine, Alta Partners, Therapy, Drug development, Breast cancer, Safety, Azacitidine, Pharmacokinetics, CDK9, Bone marrow, Pharmaceutical industry

Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.

Key Points: 
  • Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of The Hebrew University of Jerusalem, in 2023 and will use the Series A funding to advance efficacy studies in AML and breast cancer.
  • “We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients.
  • In a Phase 1 study in heavily pre-treated R/R AML patients, monotherapy BTX-A51 demonstrated a favorable safety profile and encouraging antileukemic activity.
  • As a next step, Edgewood initiated a study of BTX-A51 in combination with azacitidine in R/R AML patients in December 2023.

Harbor Health Secures $95.5 Million in New Funding to Expand and Enhance Primary & Specialty Care Services in Central Texas

Retrieved on: 
星期四, 一月 11, 2024
Harbor, Total, Health, Alta Partners, Partnership, Insurance, History, University, Map, Communication, Organization, Clay, News, Appetite, Growth

AUSTIN, Texas, Jan. 11, 2024 /PRNewswire/ -- Harbor Health, a primary and specialty clinic group whose mission is to put the consumer at the center of their own health, today announced that it has secured an additional $95.5 million in funding. General Catalyst leads this additional round of funding with strong participation by Alta Partners and continued support by 8VC. Total investment to date is more than $128 million.

Key Points: 
  • Harbor Health is leading the transformation of care that employers, providers and consumers alike are all seeking
    This additional funding will allow for continued growth in providing primary care services, broadening the scope of specialty care offerings, and developing plan designs that support care journeys co-created by consumers and their clinicians.
  • Texas employers can use these plan designs to lower their costs while incorporating an improved, coordinated care system that results in healthier and happier employees.
  • Harbor Health was founded by Dr. Clay Johnston, Eric Scott (from 8VC) and Tony Miller.
  • "We have built a geographically dense care model that is organized around integrated practice units and focused on member health conditions.

Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease

Retrieved on: 
星期二, 十二月 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, TED, IND, Alta Partners, FDA, IPF, Cell proliferation, Therapy, MHRA, Cancer, Pharmacokinetics, Medicine, Series, Collagen, Patient, CTA, Pharmaceutical industry

The syndicate also included new investors BVF Partners and Catalio Capital Management as well as existing investors, Alta Partners and Longwood Capital.

Key Points: 
  • The syndicate also included new investors BVF Partners and Catalio Capital Management as well as existing investors, Alta Partners and Longwood Capital.
  • Proceeds from this financing will support the LASN01 clinical program and advance IND-enabling activities for LASN500.
  • The clinical program for LASN01 is focused primarily in TED with a cohort in IPF in the Phase 1 program.
  • “The proceeds allow us to advance LASN01 Phase 1 and 2 clinical programs and develop a subcutaneous formulation for LASN01.

Getty Images Reports Third Quarter 2023 Results

Retrieved on: 
星期二, 十一月 14, 2023
Getty, Generative, 2011 Rugby World Cup, Amazon, Editorial, Lawsuit, Synthetic media, BBC Studios, Unsplash, LTM, Insurance, KPI, NVIDIA, COVID-19, Alta Partners, Key, BBC, Partnership, Table, Growth, API, Court, Getty Images, E-commerce, Music

Note, KPI comparisons to periods prior to trailing twelve-months ended September 30, 2023 reflect some COVID-19 impact.

Key Points: 
  • Note, KPI comparisons to periods prior to trailing twelve-months ended September 30, 2023 reflect some COVID-19 impact.
  • Third Quarter 2023 Business Highlights:
    In partnership with NVIDIA, launched Generative AI by Getty Images, a unique service which addresses fundamental customer needs.
  • Trained solely on Getty Images’ content, the service is high-quality, commercially-safe, creator-responsible and comes with uncapped indemnification.
  • The following tables summarize Getty Images updated fiscal year 2023 guidance:

MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates

Retrieved on: 
星期二, 十一月 14, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, MBrace, TPG, Breast, Spacecraft, Therapy, State university system, Annexin A5, ADC, Clinical trial, Patient, Doctor of Philosophy, Ng, Rutgers University, Cancer, Alta Partners, MBA, Clark W. LeMasters Jr., NSCLC, Pharmaceutical industry, Venrock

Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101.

Key Points: 
  • Funds will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101.
  • The round also included new investors Avidity Partners and Cowen Healthcare Investments, as well as existing Series A investors, Venrock and Alta Partners.
  • MBrace has generated extensive preclinical data on novel drug candidates in-licensed from Rutgers, The State University of New Jersey.
  • XinThera is a subsidiary of Gilead Pharmaceuticals that is focused on small molecule discovery and development of oncology and immunology therapeutics.

Free Market Health Closes $20M Equity Financing to Accelerate Innovation in the Specialty Drug Fulfillment Ecosystem

Retrieved on: 
星期三, 十一月 1, 2023
Spend, Conditional sentence, Growth, Prescription, Partnership, Pharmacy, NN Investment Partners, Patient, Alta Partners, Health care, Hospital, Nursing

PITTSBURGH, Nov. 1, 2023 /PRNewswire/ -- Free Market Health, a healthcare technology company transforming the specialty pharmacy ecosystem with a care-driven marketplace platform, today announced a $20M Series B fundraise led by Questa Capital, a leading healthcare venture capital firm that invests in breakout growth companies, with participation from existing investors Alta Partners, Highmark Ventures, and 653 Investment Partners. New funds will be used to execute on significant business growth, launch channel partnership opportunities, and scale the company's care-driven marketplace platform. Ryan Drant, Founder and Managing Partner at Questa Capital, will join the company's Board of Directors.

Key Points: 
  • Free Market Health partners with payers on a new approach to their specialty drug management program.
  • The Free Market Health platform drives efficiency, facilitates transparent and equitable access to specialty drug prescriptions for specialty pharmacies, ensures members are serviced by a pharmacy equipped to meet their unique needs, and lowers overall specialty drug spend through real-time market competition.
  • Free Market Health also partners with Highmark Wholecare parent company, Highmark Health, to support Highmark Health's commercial members on specialty medications.
  • Led by specialty pharmacy industry veterans, Free Market Health deeply understands the complexities of the specialty drug channel and is committed to improving the specialty pharmacy experience for all stakeholders.

Altas Partners Closes US$4 Billion Fund

Retrieved on: 
星期三, 七月 5, 2023
Professional Services, Business, Finance, Alta Partners, Partnership, Trust, Fund, Partner, Altas

Altas Partners (“Altas”) announced today the final closing of its third fund, Altas Partners Holdings III (Fund III), with US$4 billion of capital commitments.

Key Points: 
  • Altas Partners (“Altas”) announced today the final closing of its third fund, Altas Partners Holdings III (Fund III), with US$4 billion of capital commitments.
  • “We are very grateful to our investors for their partnership and confidence in Altas and our team," said Andrew Sheiner, CEO of Altas Partners.
  • Since inception in 2012, we’ve acquired ten market-leading businesses, and are poised to complete our eleventh investment in a few months, our first in more than two years, consistent with our selective approach.”
    Fund III closed at its $4 billion target and is one third larger than Altas' $3 billion predecessor fund.
  • “We are fortunate to have earned the support and trust of an exceptional group of global investors,” added Aryella Frommer, Partner at Altas.

BetterVet Adds Two New Executives to the Leadership Team, Nicole Leiter, as COO, and Mark Prather as Board Member

Retrieved on: 
星期二, 一月 24, 2023
MD, International business, University, World Veterinary Association, Fort Hays, Health, MBA, UCLA, AVMA, Leiter, Growth, Pet, University of Colorado Denver Business School, Business administration, Vanderbilt University, Walgreens, Hospital, McKesson Corporation, Emergency medicine, Alta Partners, University of Nebraska Medical Center, Denver Health Medical Center, Nebraska Medicine, Fort Hays State University, University of Nebraska–Lincoln, Management, Pharmacy, Biochemistry, Science

Nicole Leiter joins BetterVet as Chief Operating Officer and Mark Prather as Board Member.

Key Points: 
  • Nicole Leiter joins BetterVet as Chief Operating Officer and Mark Prather as Board Member.
  • Following her time at Walgreens, Leiter joined the senior leadership team at McKesson building a new customer segment focused on digital-first pharmacies.
  • Dr. Prather looks forward to bringing his home-based medical care expertise to his BetterVet Board of Directors role.
  • "I am happy to offer my perspective as a doctor and leader to the BetterVet Board," says Dr. Prather.